Colonoscopy, inflammatory bowel disease

S. Samuel; K. Ragunath

doi:10.1055/s-0032-1326295

Endoscopy, Inhaltsverzeichnis

Endoscopy 2013; 45(04): 289-291
DOI: 10.1055/s-0032-1326295

Endoscopy essentials

Colonoscopy, inflammatory bowel disease

Autoren

S. Samuel

National Institute for Health Research Biomedical Research Unit, Nottingham Digestive Diseases Centre, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
K. Ragunath

National Institute for Health Research Biomedical Research Unit, Nottingham Digestive Diseases Centre, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

Abstract

Volltext

Referenzen

References
1 Ignjatovic A, East JE, Subramanian V et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012; 107: 885-890
2 Rutter MD, Saunders BP, Wilkinson KH et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038
3 Kiesslich R, Fritsch J, Holtmann M et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888
4 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535
5 Bisschops R, Bessissow T, Baert FJ et al. Chromoendoscopy versus narrow band imaging in ulcerative colitis: a prospective randomized controlled trial. Gastrointest Endosc 2012; 75: AB148
6 Travis SP, Schnell D, Krzeski P et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-542
7 Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005; 3: 11-24
8 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
9 Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1 (5375) 89-92
10 Sandborn WJ, Regula J, Feagan BG et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009; 137: 1934-1943
11 Samuel S, Bruining DH, Loftus Jr EV et al. Endoscopic skipping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol 2012; 10: 1253-1259
12 Siddiki HA, Fidler JL, Fletcher JG et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol 2009; 193: 113-121
13 Behr MA. The path to Crohn’s disease: is mucosal pathology a secondary event?. Inflamm Bowel Dis 2010; 16: 896-902
14 Van Kruiningen HJ, Colombel JF. The forgotten role of lymphangitis in Crohn’s disease. Gut 2008; 57: 1-4
15 D’Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-2224
16 Roseth AG, Fagerhol MK, Aadland E et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793-798
17 Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169